Pseudo-Progression and the Neutrophil-To-Lymphocyte Ratio in Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors: A Case–Control Study

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s228138
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?

Current Treatment Options in Oncology
OncologyPharmacology
2019English

P2.01-82 Neutrophil-To-Lymphocyte Ratio Complements the Prognostic Ability of PD-L1 in Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Neutrophil-To-Lymphocyte Ratio as an Early Marker of Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Nivolumab

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2018English

Initial Experience After Transition to Immune Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer Treated in a Rural Healthcare Region

Cureus
2020English

Peripheral Blood Markers Identify Risk of Immune‐Related Toxicity in Advanced Non‐Small Cell Lung Cancer Treated With Immune‐Checkpoint Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2019English

Neutrophil-Lymphocyte Ratio Predicts Recurrence in Patients With Resected Stage 1 Non-Small Cell Lung Cancer

Journal of Cardiothoracic Surgery
CardiologyCardiovascular MedicineMedicinePulmonaryRespiratory MedicineSurgery
2018English

Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)

Open Access Journal of Oncology and Medicine
2018English

Immune Checkpoint Modulation for Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy